Approvals· July 3, 2026 · 17 min read
Icotyde (icotrokinra) FDA approval and oral IL-23 psoriasis access
By Ran Chen#FDA Approval#Dermatology#Immunology
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.
Approvals· July 3, 2026 · 17 min read
Lynavoy (linerixibat) FDA approval: first IBAT inhibitor for PBC pruritus
By Ran Chen#FDA Approval#GI and Liver#Rare Disease
Approvals· July 3, 2026 · 17 min read
Yuviwel (navepegritide) FDA approval and once-weekly achondroplasia access
Pricing & Access· June 30, 2026 · 18 min read
China's 2026 Dual-Track Drug Catalog: Reading NHSA Preliminary Numbers
By Ran Chen#China#Market Access#Drug Pricing
Biosimilars· June 29, 2026 · 18 min read
Soliris Biosimilar Cliff: NMOSD Exclusivity Expiry and Payer Step Edits
By Ran Chen#Biosimilars#Interchangeability#Payer Policy
Policy· June 28, 2026 · 17 min read
Medicaid Drug Rebate Program Explained: AMP, Best Price, and the CPI Penalty
By Ran Chen#Medicaid#Drug Pricing#Payer Policy
Pricing & Access· June 24, 2026 · 25 min read
Amgen Portfolio Dossier: Purple Book Biologics and Biosimilars
By Ran Chen#Purple Book#Biosimilars#Drug Pricing
Biosimilars· June 22, 2026 · 20 min read
Poherdy (Pertuzumab-dpzb): FDA Approval and Payer Dynamics
By Ran Chen#Biosimilars#FDA Approval#Oncology
Policy· June 21, 2026 · 5 min read
Building the AMCP dossier: a guide to the version 5.0 format and value evidence template
Pricing & Access· June 21, 2026 · 6 min read